Skip to main content
BIAF
NASDAQ Industrial Applications And Services

Nasdaq Delisting Notice: bioAffinity Falls Below $1 Bid, Ineligible for Standard Cure Period

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.599
Mkt Cap
$3.942M
52W Low
$0.56
52W High
$13.5
52W Position info
6.9% above low
Off High info
96% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

BIAF is trading near its 52-week low of $0.56 (6.9% above the low) on light trading volume (0.3× avg).

Summary

bioAffinity Technologies received a Nasdaq delisting notice for failing the $1 minimum bid price rule and is ineligible for the standard cure period due to a prior reverse split. The company will appeal, but delisting risk is acute given its fragile financial position.


Key Events · Legal and Risk Events · BIAF

  • Nasdaq Delisting Notice Received

    On July 30, 2026, Nasdaq notified bioAffinity that its stock closed below $1.00 for 30 consecutive business days, violating the minimum bid price requirement.

  • Ineligible for Standard 180-Day Cure

    Due to a 1-for-30 reverse stock split on September 19, 2025, the company is not eligible for the usual 180-day compliance period under Nasdaq Rule 5810(c)(3)(A)(iv).

  • Appeal Planned for August 6

    The company intends to appeal the Staff Determination on August 6, 2026, which will stay delisting pending a hearing before a Nasdaq Hearings Panel.

  • No Assurance of Extension or Compliance

    The company cannot guarantee the Panel will grant an extension or that it will regain compliance with the bid price rule, putting its Nasdaq listing at immediate risk.


Analysis · BIAF · Industrial Applications And Services

A Nasdaq Staff Determination landed on July 30, 2026, after bioAffinity Technologies' stock closed below $1 for 30 consecutive business days. Because the company executed a 1-for-30 reverse split in September 2025, it is not eligible for the standard 180-day compliance period. An appeal is planned for August 6, which stays delisting pending a hearing, but there is no guarantee the Panel will grant an extension or that the company can regain compliance. With a market cap under $4 million and a cash runway that was already critical as of June 2026, a delisting would severely impair liquidity and access to capital, threatening the company's survival.

At the time of this filing, BIAF was trading at $0.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.56 to $13.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIAF - Latest Insights

BIAF
Jul 07, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8401
Real-time Price: $0.5986 info
Change: -$0.2415 (-29%) info
Market Cap: $3.942M info
BIAF
Jul 07, 2026, 8:54 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8355
Real-time Price: $0.5986 info
Change: -$0.2369 (-28%) info
Market Cap: $3.942M info
BIAF
Jun 30, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.830
Real-time Price: $0.5986 info
Change: -$0.2314 (-28%) info
Market Cap: $3.942M info
BIAF
Jun 30, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.830
Real-time Price: $0.5986 info
Change: -$0.2314 (-28%) info
Market Cap: $3.942M info
BIAF
Jun 18, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.8389
Real-time Price: $0.5986 info
Change: -$0.2403 (-29%) info
Market Cap: $3.942M info